Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CMV pp65 antigen-specific cytotoxic T cell
- Molecular classification
- Other (antigen-specific cytotoxic T lymphocyte; functionally a CD8+ effector T cell subset)
01
Overview
CMV pp65 antigen-specific cytotoxic T cells are adaptive immune cells (primarily CD8+ T cells, though CD4+ specificity exists[1]) capable of identifying and killing CMV-infected cells presenting pp65-derived peptides on HLA class I molecules[3][2]. These T cells drive polyfunctional cytotoxic immune responses characterized by the production of interferon-γ, TNF-α, perforin, and mobilization of CD107a upon activation[1][2]. They are essential for CMV control in healthy and immunocompromised individuals, and their adoptive transfer is used therapeutically in contexts such as stem cell transplantation to restore antiviral immunity[4]. Monitoring the presence and function of pp65-specific CTL is a biomarker for CMV-specific immunity in clinical settings[3][2]. The term refers to a cell population, not a molecular drug target, and should not be confused with an individual molecule, receptor, or protein.
- Other names
- CMV pp65-specific CTLCytomegalovirus pp65-specific cytotoxic T lymphocyteCMV pp65-responsive CD8+ T cellCMV-pp65 antigen reactive T cell
02
Biological functions
Immune responseCell-mediated cytotoxicityPathogen clearanceImmunosurveillancePolyfunctional cytokine secretion (including interferon-γ, TNF-α, IL-2, perforin)
03
Disease associations
Infection (CMV control)Immunodeficiency-related complicationsPotential role in cancer immunotherapy (experimental)
04
Safety considerations
Potential for graft-versus-host disease (GVHD) in adoptive T cell therapyRisk of off-target cytotoxicity if cells recognize self-antigen or are not fully specificNeed for strict HLA matching to prevent immunopathology
05
Biomarkers
Frequency and function of pp65-specific CTL (measured by IFN-γ ELISPOT, cytokine secretion, CD107a mobilization, perforin expression)CMV IgG levels (used in seropositive individuals to correlate with T cell response size)
Beyond the preview
Go deeper on CMV pp65 antigen-specific cytotoxic T cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMV pp65 antigen-specific cytotoxic T cell.